65,437 trials
Allergic Contact Dermatitis
Primary: Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0) — 14.53; 16.03; 109.1; 110.7 pg/ml
Stress Disorders, Post-Traumatic · Intimate Partner Violence · Alcohol-Related Disorders
Primary: Change in Number of Health Risks — 1.38; 1.05 number of risks
Multiple Myeloma
Primary: Median Progression-Free Survival (PFS) — 8.5 Months
Humans · Young Adult · Health
Primary: The Most Effective Capacitance Shortwave Technique in Relation to Temperature Increase and Heat Conservation Measured by Infrared Thermography — 1.72; 0.58; 0.94; 7.9…
Acquired Immunodeficiency Syndrome (AIDS)
Primary: Change in Quality of Life — 5.87; 5.17; 5.68; 5.06 score on a scale
Diabetes Mellitus, Type 2
Primary: Number of Enrollments in the Study Over One Year — 4; 2 Participants
Healthy Adults
Primary: Safety (Evaluation of Adverse Events) — 17; 17 Participants
Atrial Fibrillation · Thromboembolism · Stroke
Primary: Number of Participants With Acute Serious Adverse Events — 83 Participants
Colonic Polyps
Primary: Feasibility and Sensitivity of OFDI Imaging in the Colon — 2; 1 Participants
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Provoked Localized Vulvodynia
Primary: Tampon Test — -2.43; -1.88 units on a scale
Plaque Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation) — 112; 254; 6 Participants — p=<0.0001
Chronic Hepatitis D Infection With Hepatitis B
Primary: HDV RNA Response at Week 24 — 15; 16; 23; 1 Participants — p=<.0001
Chronic Pain · Low Back Pain · Heat
Primary: Pain Rating — -1.40; -0.68 reduction in pain score on a scale — p=<0.05
Cystic Fibrosis
Primary: Change in Percent Predicted FEV1 — 1.633; 0.800; 0.890 change from baseline in ppFEV1